EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 99 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR Two Large Studies with New Screening Tests Show Promise for Increasing... March 18, 2024 Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy... January 14, 2025 NCI Part of Federal Effort to Evaluate Antibody Tests for Novel... May 5, 2020 Child Cancer Patient And His Dad Have A Little Fun When... October 3, 2019 Load more HOT NEWS High-Fat Diet or Diabetes Drug May Enhance Response to Targeted Cancer... ΚΑΡΚΙΝΟΣ ΤΡΑΧΗΛΟΥ ΜΗΤΡΑΣ Young Tulsa Mom Grows Closer To Her Own Mom During Almost... Screening for Many Cancers with One Test: Uncertainty Abounds
